Posted by Michael Wonder on 02 Apr 2019
Teva’s Ajovy receives EU approval offering patients the first and only anti-CGRP treatment with both quarterly and monthly dosing for the prophylaxis of migraine in adults
1 April 2019 - In clinical trials, many patients on Ajovy experienced significant reductions of at least 50% in the number of monthly migraine days with reduction observed as early as week one.
Teva Pharmaceutical Industries today announced that the European Commission has granted the marketing authorisation for Ajovy (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month. Ajovy is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Ajovy is the first and only anti-CGRP drug approved in the European Union and the United States that is designed for the prevention of migraine that offers both quarterly and monthly dosing options for the prophylatic treatment of migraine.
